Yazar "Yiğit Kaya, Süreyya" için listeleme
-
Clinical outcomes and treatment patterns of primary central nervous system lymphoma: Multicenter retrospective analysis
Güven, Serkan; Yavuz, Boran; Erdoğan Yücel, Elçin; Karataş, Aylin Fatma; Özsan, Güner Hayri; Demirkan, Fatih; Ündar, Bülent; Özcan, Mehmet Ali; Kiper, Hatice Demet; Çetintepe, Tuğba; Göçer, Mesut; Kurtoğlu, Erdal; Balık Aydın, Berrin; Sevindik, Ömür Gökmen; Yiğit Kaya, Süreyya; Alacacıoğlu, İnci (Kare Publishing, 2023)Objectives: Primary central nervous system lymphoma (PCNSL) is a rare malignant disease with poor prognosis. Its low incidence leads to challenges in decision-making for treatment. As a matter of fact, there is still no ... -
Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience
Kılıç Güneş, Ebru; Yiğit Kaya, Süreyya; Yaman, Fatih; Yeniay, Mustafa Kemal; Vural, Kurtuluş; Cömert, Melda; Sevindik, Ömür Gökmen; Andıç, Neslihan; Dağdaş, Simten; Nizam Özen, İlknur; Kaynar, Leylagül; Yavaşoğlu, Filiz; Özet, Gülsüm; Karakuş, Volkan; Aylı, Meltem (2024)Introduction: Thrombocytopenia is among the most common complications following hematopoietic stem cell transplantation and is associated with increased mortality and morbidity with no standard treatment yet. In this ... -
Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
Yiğit Kaya, Süreyya; Aşkın, Abdullah Emre; Bektaş, Şebnem; Çakır, Aslı; Gökmen Sevindik, Ömür (Elsevier Ltd, 2023)Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains an effective option for the treatment of intermediate and high-risk Acute myeloid leukemia (AML). Post-transplant lymphoproliferative disorder (PTLD) ... -
Pegaspargase, venetoclax, and nelarabine: A successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed/refractory T-cell acute lymphoblastic leukemia patient
Yiğit Kaya, Süreyya; Bektaş, Şebnem; Aşkın, Abdullah Emre; Balık Aydın, Berrin; Mutlu, Yaşa Gül; Sevindik, Ömür Gökmen (Springer, 2023)... -
Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: First reported case
Mutlu, Yaşa Gül; Yiğit Kaya, Süreyya; Maral, Senem; Melek, Elif; Başlar, Zafer; Kaynar, Leylagül; Sevindik, Ömür Gökmen (Frontiers Media SA, 2023)Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific ... -
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience
Yiğit Kaya, Süreyya; Mutlu, Yaşa Gül; Malkan, Ümit Yavuz; Mehtap, Özgür; Keklik Karadağ, Fatma; Korkmaz, Gülten; Elverdi, Tuğrul; Saydam, Güray; Özet, Gülsüm; Ar, Muhlis Cem; Melek, Elif; Maral, Senem; Kaynar, Leylagül; Sevindik, Ömür Gökmen (2024)Background: Hairy cell leukemia (HCL) is a rare mature B-cell malignancy that is primarily treated with purine analogues. However, relapse remains a significant challenge, prompting the search for alternative therapies. ...